Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PST-611 open-label multiple-dose trial in geographic atrophy secondary to age-related macular degeneration
2025-525008-12-00Phase 2Authorised
- Sponsor
- PulseSight Therapeutics
- Start
- Jun 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EYS611 in age-related macular degeneration (AMD), sponsored by PulseSight Therapeutics. Primary endpoints: Ocular adverse events and treatment-emergent adverse events and Ophthalmic examination findings. Planned start Jun 2026; status: authorised.
02
Drugs
EYS611
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2025-525008-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525008-12-00.